CDKN3
CDKN3 (cyclin-dependent kinase inhibitor 3, also known as KAP or CDI1) is a dual specificity phosphatase that may play a role in cell cycle regulation. It dephosphorylates CDK2 and so limits activation of this cyclin-dependent kinase. Browse Assay Genie's current range of CDKN3 research reagents below, or read on for the biology behind the target.
CDKN3 is a dual specificity phosphatase that is active toward substrates containing either phosphotyrosine or phosphoserine residues. It dephosphorylates CDK2 at Thr-160 in a cyclin-dependent manner. Because phosphorylation at this site is needed for CDK2 activity, removal of the phosphate prevents activation of the kinase. This activity is consistent with the proposed role of the protein in cell cycle regulation, and with its original identification as a cyclin-dependent kinase inhibitor.
The CDKN3 protein belongs to the protein-tyrosine phosphatase family and, within the HGNC classification, to the CDC14 phosphatases gene group. Its UniProt entry lists a cytoplasmic location in the perinuclear region. The CDKN3 gene produces alternatively spliced transcript variants that encode different isoforms. The mouse ortholog is listed as Cdk3 and the rat ortholog as Cdkn3 in the data supplied.
The protein is also known as KAP and CDI1, names that appear in older literature on cyclin-dependent kinase-associated phosphatases. Although it shares its name with the CDKN1 and CDKN2 families of cyclin-dependent kinase inhibitors, CDKN3 acts as an enzyme rather than as a stoichiometric inhibitor. The gene has been reported to be deleted, mutated or overexpressed in several kinds of cancers, which makes it a point of interest for researchers studying cell cycle control and tumour biology.
CDKN3 dephosphorylates CDK2 and may play a role in controlling progression through the cell cycle.
The CDKN3 gene has been reported to be deleted, mutated or overexpressed in several kinds of cancers.
As a dual specificity phosphatase, CDKN3 acts on both phosphotyrosine and phosphoserine substrates, making it a model for substrate selectivity.
CDKN3 removes the activating phosphate at Thr-160 of CDK2 in a cyclin-dependent manner, preventing kinase activation.
CDKN3 is a dual specificity phosphatase that acts on phosphotyrosine and phosphoserine residues. It dephosphorylates CDK2 at Thr-160 in a cyclin-dependent manner, preventing CDK2 activation, and may play a role in cell cycle regulation.
CDKN3 is also called KAP and CDI1, and its full name is cyclin dependent kinase inhibitor 3. Alternatively spliced transcript variants of the gene have been found, and they encode different isoforms of the protein.
Orthologs are listed in mouse (Cdk3) and rat (Cdkn3), so check the datasheet of any product for its validated reactivity. The human gene has been reported to be deleted, mutated or overexpressed in several kinds of cancers.
Other cyclin-dependent kinase inhibitors and cell cycle regulators with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q16667; product specifications from Assay Genie datasheets.